COMPANY
TwoStep Therapeutics
TwoStep Therapeutics is developing a pipeline built around a versatile peptide that selectively binds multiple tumor-associated targets—a feature that enables the delivery of diverse payloads across a wide range of solid tumor types. From company website Source · Oct 12, 2026
Since the raise (Sep 9, 2026): 1 of 1 open job was first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Want to join TwoStep? | San Carlos, CA, United States | Dec 4, 2024 | Oct 8, 2026 |
Funding and NIH signals
- SEC Form D raise Raised $21.11M (Form D filed Jan 20, 2026); 1 role open. SEC Form D 0002015273-26-000002 (Jan 20, 2026)
Evidence (1 event)
- Jan 20, 2026 · SEC Form D 0002015273-26-000002
Name of Issuer: TwoStep Therapeutics, Inc.; CIK: 2015273; Address: San Carlos, CA; Submission type: D; Filing date: 2026-01-20; Industry Group: Other; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 62209510; Total Amount Sold: 21109518; Federal exemptions: 06b
- Jan 20, 2026 · SEC Form D 0002015273-26-000002
- NIH award NIH awarded $1.3M (SBIR Phase II 1R44CA306597-01A1, new, notice Sep 4, 2026); 1 role open. NIH RePORTER 1R44CA306597-01A1 (Sep 4, 2026)
Evidence (1 event)
- Sep 4, 2026 · NIH RePORTER 1R44CA306597-01A1
Organization: TWOSTEP THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 1R44CA306597-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1303289; Administering IC: National Cancer Institute; Project title: Developing a broadly applicable targeted peptide-drug conjugate for the treatment of solid tumors; Organization type: Domestic For-Profits
- Sep 4, 2026 · NIH RePORTER 1R44CA306597-01A1
Timeline
- Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
- Raise Private equity round — Series A: $62.5M (total, as published), announced Sep 9, 2026. Source: company's own press page. source ↗
- Trial start 1: A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors source ↗
Upcoming milestones
- 2028-08 (ESTIMATED) · 1 · A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors · NCT07814248
Open jobs 1
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Want to join TwoStep? | San Carlos, CA, United States | Dec 4, 2024 | Oct 8, 2026 | Mid |
Funding
- Private equity round — Series A: $62.5M (total, as published), announced Sep 9, 2026. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | 1 | Recruiting | Sep 2, 2026 | 2028-08 (estimated) |
NIH awards 1
- NIH award 1R44CA306597-01A1 FY2026: $1,303,289 awarded for that fiscal year; activity R44 (SBIR); PI MILLER, CAITLYN; recipient as written: TWOSTEP THERAPEUTICS, INC., SAN CARLOS, CA. Developing a broadly applicable source ↗
Connect
See your connections at TwoStep Therapeutics on LinkedIn (search by name, results not checked)